Additionally, in a collection of 50 matched primary and metastatic lesions from breast cancer patients, using SOD2 as a marker, we observed a significant increase in activation of the SIRT3 axis of the UPRmt, in metastatic lesions when compared with primary lesions. This evidence concerns the gene SOD2 and breast cancer.